Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20280936 | 1.00 | HPSE (1.00) | HPSE | |
| SCHEMBL29424176 | 1.00 | HPSE (1.00) | HPSE | |
| SCHEMBL6821869 | 0.94 | HPSE (0.89) | HPSE | |
| SCHEMBL6821844 | 0.92 | HPSE (1.00) | HPSE | |
| SCHEMBL6822223 | 0.90 | HPSE (0.90) | HPSE | |
| SCHEMBL6822193 | 0.90 | HPSE (1.00) | HPSE | |
| SCHEMBL6822288 | 0.89 | HPSE (1.00) | HPSE | |
| SCHEMBL6824237 | 0.89 | HPSE (1.00) | HPSE | |
| SCHEMBL7118415 | 0.89 | HPSE (0.87) | HPSE | |
| SCHEMBL6818350 | 0.88 | HPSE (0.83) | HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4518857-A1 | METHODS OF TREATING ALLOGRAFT REJECTION | Bargent Therapeutics Pty Limited (AU) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023212768-A1 | METHODS OF TREATING ALLOGRAFT REJECTION | Bargent Therapeutics Pty Limited (AU) | 2023-11-09 | — | — | WO | disclosed |
| US-20200093852-A1 | Methods of Treating Ocular Disorders | Beta Therapeutics Pty Ltd (AU) | 2020-03-26 | — | — | US | disclosed |
| EP-3554505-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2019-10-23 | — | — | EP | disclosed |
| EP-3104873-B1 | FGF-8 FOR USE IN TREATING DISEASES OR DISORDERS OF ENERGY HOMEOSTASIS | UNIV MUENCHEN TECH (DE) | 2019-09-04 | — | — | EP | disclosed |
| WO-2018107226-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2018-06-21 | — | — | WO | disclosed |
| US-20160168567-A1 | UNA SINGLE STRANDED OLIGOMERS FOR THERAPEUTICS | MARINA BIOTECH, INC. | 2016-06-16 | — | — | US | disclosed |
| WO-2004046122-A2 | BENZOXAZOLE, BENZTHIAZOLE AND BENZIMIDAZOLE ACID DERIVATIVES AND THEIR USE AS HEPARANASE INHIBITORS | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093852-A1 | Methods of Treating Ocular Disorders | ALDH1A2, HPSE, RB1 | HPSE 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.